Mechanisms of trastuzumab resistance and their clinical implications

被引：60
|
作者：
Lan, KH
Lu, CH
Yu, DH
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
来源：
TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE | 2005年 / 1059卷
关键词：
trastuzumab; resistance; ErbB2; breast cancer; PI3K; PTEN;
D O I：
10.1196/annals.1339.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trastuzumab (Herceptin"') is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.
引用
收藏
页码：70 / 75
页数：6
相关论文
共 50 条
  • [41] Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications
    Tousoulis, D.
    Tsarpalis, K.
    Cokkinos, D.
    Stefanadis, C.
    DIABETES OBESITY & METABOLISM, 2008, 10 (10): : 834 - 842
  • [42] Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
    Cara, S
    Tannock, IF
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 23 - 27
  • [43] Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer
    Liu, Ying
    Ao, Xiang
    Ji, Guoqiang
    Zhang, Yuan
    Yu, Wanpeng
    Wang, Jianxun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Molecular mechanisms of trastuzumab-mediated cardiomyopathy: Implications of autophagy in trastuzumab-induced cardiotoxicity
    Mohan, Nishant
    Shen, Yi
    Wu, Wen J.
    CANCER RESEARCH, 2016, 76
  • [45] Identification of molecular mechanisms of acquired resistance to trastuzumab in gastric cancer
    Sampera, A.
    Gelabert-Baldrich, M.
    Sanchez-Martin, F. J.
    Dalmases, A.
    Arpi, O.
    Iglesias, M.
    Martinez, A.
    Rovira, A.
    Albanell, J.
    Montagut, C.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S124 - S125
  • [46] HER2 therapy: Molecular mechanisms of trastuzumab resistance
    Rita Nahta
    Francisco J Esteva
    Breast Cancer Research, 8
  • [47] Mechanisms responsible for resistance to Trastuzumab inhuman breast cancers.
    Valabrega, G
    Montemurro, F
    Sarotto, I
    Petrelli, A
    Aglietta, M
    Giordano, S
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6087S - 6088S
  • [48] HER2 therapy - Molecular mechanisms of trastuzumab resistance
    Nahta, Rita
    Esteva, Francisco J.
    BREAST CANCER RESEARCH, 2006, 8 (06):
  • [49] Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
    Li, Guangmin
    Guo, Jun
    Shen, Ben-Quan
    Yadav, Daniela Bumbaca
    Sliwkowski, Mark X.
    Crocker, Lisa M.
    Lacap, Jennifer A.
    Phillips, Gail D. Lewis
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) : 1441 - 1453
  • [50] Activity and resistance of trastuzumab according to different clinical settings
    Tagliabue, Elda
    Campiglio, Manuela
    Pupa, Serenella M.
    Menard, Sylvie
    Balsari, Andrea
    CANCER TREATMENT REVIEWS, 2012, 38 (03) : 212 - 217
12345